8-K
filed May 1, 2026, 7:59 PM ET
ticker ADVB
CIK 0001941029
M&A
confidence high
sentiment neutral
materiality 0.90
Advanced Biomed Inc. (ADVB): M&A transaction — Advanced Biomed completes AI pivot with acquisition of Acellent Technologies
Advanced Biomed Inc.
- Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.
- Strategic pivot from life sciences to AI development; CEO Yi Lu mutually separated, receives 39,999 shares as severance.
- Xiaomin Chen appointed CEO, director, and chairman effective April 28; he has 20+ years AI experience including Google.
- Chen's base salary set at $12,000/month; eligible for bonuses and equity incentives.
- Chen is the sole shareholder of the acquired entity, creating a direct material interest in the transaction.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Advanced Biomed Inc. issued 270,000 shares of common stock to Mr. Xiaomin Chen for $1,080,000.
- Security
- common stock
- Shares
- 270,000 shares
- Purchaser
- Mr. Xiaomin Chen
- Consideration
- $1,080,000
Exact text from the filing
n aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026. Item 3.02 Unregistered Sales
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Xiaomin Chen was appointed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..
- Action
- appointed
- Role
- Chief Executive Officer, director and Chairman of the Board
Exact text from the filing
the Board of Directors appointed Mr. Xiaomin Chen as Chief Executive Officer, director and Chairman of the Board of the Company, effective as of April 28, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Yi Lu departed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..
- Action
- mutually agreed to separate
- Role
- Chief Executive Officer, director and Chairman of the Board
Exact text from the filing
The Company and Mr. Yi Lu, the Company’s Chief Executive Officer, director and Chairman of the Board, have mutually agreed that a leadership transition is necessary and in the best interests of the Company.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Advanced Biomed Inc. completed an acquisition involving Acellent Technologies (Hong Kong) Co. Limited for $1,080,000 (closed 2026-04-30).
- Action
- acquisition
- Counterparty
- Acellent Technologies (Hong Kong) Co. Limited
- Consideration
- $1,080,000
- Closing
- 2026-04-30
Exact text from the filing
Pursuant to the Share Purchase Agreement, the Company agreed to acquire 100% of the equity interest in the Target in exchange for the issuance of 270,000 shares of the Company’s common stock, par value $0.001 per share, valued at $4.00 per share, for an aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.